CELYAD ONCOLOGY (CYAD.BR) Stock Price & Overview
EBR:CYAD • BE0974260896
Current stock price
The current stock price of CYAD.BR is 0.313 EUR. Today CYAD.BR is down by -3.69%. In the past month the price decreased by -1.57%. In the past year, price decreased by -42.04%.
CYAD.BR Key Statistics
- Market Cap
- 14.01M
- P/E
- 31.30
- Fwd P/E
- N/A
- EPS (TTM)
- 0.01
- Dividend Yield
- N/A
CYAD.BR Stock Performance
CYAD.BR Stock Chart
CYAD.BR Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to CYAD.BR. When comparing the yearly performance of all stocks, CYAD.BR is one of the better performing stocks in the market, outperforming 77% of all stocks.
CYAD.BR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CYAD.BR. CYAD.BR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
CYAD.BR Earnings
CYAD.BR Forecast & Estimates
CYAD.BR Groups
Sector & Classification
CYAD.BR Financial Highlights
Over the last trailing twelve months CYAD.BR reported a non-GAAP Earnings per Share(EPS) of 0.01. The EPS increased by 109.53% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 3952.38% | ||
| ROA | 19.31% | ||
| ROE | 34.07% | ||
| Debt/Equity | 0 |
CYAD.BR Ownership
CYAD.BR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 30.67 | 43.675B | ||
| ARGX | ARGENX SE | 30.8 | 43.625B | ||
| 22UA | BIONTECH SE-ADR | N/A | 21.343B | ||
| ABVX | ABIVAX SA | N/A | 8.381B | ||
| 2X1 | ABIVAX SA | N/A | 8.341B | ||
| GLPG | GALAPAGOS NV | N/A | 1.625B | ||
| GXE | GALAPAGOS NV | N/A | 1.607B | ||
| NANO | NANOBIOTIX | N/A | 1.349B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 1.073B | ||
| PHARM | PHARMING GROUP NV | 51.86 | 1.066B | ||
| PHGN | PHARMING GROUP NV | 50.57 | 1.066B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 1.019B | ||
| IVA | INVENTIVA SA | N/A | 905.616M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Brussels Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About CYAD.BR
Company Profile
Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 12 full-time employees. The company went IPO on 2013-07-05. The firm is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The firm develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The firm's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). The company also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).
Company Info
IPO: 2013-07-05
CELYAD ONCOLOGY
Rue Andre Dumont 9
Mont-Saint-Guibert BRABANT-WALLON BE
Employees: 18
Phone: 3210394100
CELYAD ONCOLOGY / CYAD.BR FAQ
What does CELYAD ONCOLOGY do?
Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 12 full-time employees. The company went IPO on 2013-07-05. The firm is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The firm develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The firm's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). The company also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).
What is the current price of CYAD stock?
The current stock price of CYAD.BR is 0.313 EUR. The price decreased by -3.69% in the last trading session.
Does CELYAD ONCOLOGY pay dividends?
CYAD.BR does not pay a dividend.
What is the ChartMill technical and fundamental rating of CYAD stock?
CYAD.BR has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the PE ratio for CYAD stock?
The PE ratio for CELYAD ONCOLOGY (CYAD.BR) is 31.3. This is based on the reported non-GAAP earnings per share of 0.01 and the current share price of 0.313 EUR.
Can you provide the market cap for CELYAD ONCOLOGY?
CELYAD ONCOLOGY (CYAD.BR) has a market capitalization of 14.01M EUR. This makes CYAD.BR a Nano Cap stock.